Regarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
28/09/2026 08:04
BRIEF-Chugai Pharmaceutical Co Ltd - Regarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA Sept 28 (Reuters) - Chugai Pharmaceutical Co Ltd 4519.T:
CHUGAI PHARMACEUTICAL CO LTD - REGARDING DISCONTINUATION OF DEVELOPMENT OF GYM329 (EMUGROBART) FOR OBESITY, RETURN OF LICENSE AND RESUMPTION OF DEVELOPMENT FOR SMA
Source text: ID:nTSub8408e
Further company coverage: 4519.T
Recent news on Chugai Pharmaceutical
See all newsRegarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Table: Chugai Pharm 6-MTH group results (IFRS)
Japan's Nikkei roars past 62,000 on earnings, Middle East optimism; JGBs rally (updated)
Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism
Japan's Nikkei closes above 60,000 for first time on earnings optimism (updated)